GAITHERSBURG, Md., May 6 /PRNewswire/ -- MedImmune today announced that it
has enhanced its leadership team to guide the company's expanded product
pipeline in the United States and abroad as well as the core scientific
research that underpins this development. Jacqueline Hall has been appointed
global vice president, product development team leadership; Lorin Roskos,
Ph.D. has been appointed vice president and global head of pharmacokinetics
(PK), pharmacodynamics (PD), and bioanalysis in translational sciences and
Beth Wensley has been appointed vice president, project management. In
addition, Erik-Jan Dekker, Ph.D. joined the organization as vice president,
international regulatory affairs, vaccines and Reginald Seeto, M.D., joins as
vice president, global strategic marketing and portfolio management.
"It is imperative that we have strong leaders who can channel the
continued growth of our product portfolio, particularly as we seek to build
out the organization globally," said David M. Mott, chief executive officer
and president. "Jacqui, Lorin, Beth, E-J and Reg have the innate talent,
industry experience and drive for results that will contribute to MedImmune's
continued leadership in biologics."
Based at MedImmune's Cambridge, UK site, Ms. Jacqueline Hall is
accountable for the strategic leadership of global product development teams
that are responsible for the generation and execution of development plans for
biologics products. She joined Cambridge Antibody Technology (CAT), now
MedImmune, in 2006 as vice president, project management. Previously, Ms. Hall
served as project leader at GlaxoSmithKline where she was responsible for the
strategic development of product candidates from selection through to market
launch. She has also held positions at SmithKline Beecham, Pharmaco-LSR and
Schering-Plough. Ms. Hall has a first-class honors degree in chemistry from
Imperial College of Science and Technology/Birbeck College, London and a
diploma in clinical science from the Welsh School of Pharmacy, Cardiff.
Dr. Lorin Roskos is responsible for managing and integrating preclinical
and clinical PK/PD and bioanalytical groups at MedImmune sites in Maryland,
California and England. Dr. Roskos became part of the MedImmune team in 2008
after a year at AstraZeneca as executive director of research and development.
Prior to AstraZeneca, Dr. Roskos spent six years at Abgenix, Inc., as the head
of PK and toxicology, and has prior experience in PK and drug metabolism at
Amgen and Eli Lilly. He holds a doctorate in pharmaceutics from the University
of Washington and a bachelor's degree in biochemistry and pharmacy from the
University of Georgia.
Ms. Beth Wensley oversees the global project management team that provides
strategic project management in driving forward the product development teams
and the overall product development portfolio. Ms. Wensley joined MedImmune in
2001, and has previously served as senior director, California operations;
director, supply chain operations; and associate director, project management.
She earned extensive project management, operational, manufacturing and
environmental, health & safety experience during her tenure with companies
such as Incyte Genomics, Raychem Corporation and Syntex Pharmaceuticals. She
holds a master's degree in business administration from Santa Clara University
and a master's in environmental science from the University of Washington. She
also has a bachelor's degree in biology from California Lutheran College and
is APICS certified from the Association for Operations Management.
Based in the Netherlands as MedImmune's new vice president, international
regulatory affairs, vaccines, Dr. Erik-Jan Dekker is leveraging his 17 years'
experience in regulatory affairs to lead MedImmune's expansion overseas. In
his previous position at Baxter Healthcare, he was the global senior director,
regulatory affairs, biologics, responsible for worldwide vaccine and
biosurgery marketing authorization applications. Prior to joining Baxter
Healthcare, Dr. Dekker was the director of regulatory affairs globally at
Laboratoire Francais du Fractionnement et des Biotechnologies in France.
Earlier in his career, Dr. Dekker held teaching positions at the University of
Utrecht and Alkwin College. From the University of Utrecht, Dr. Dekker holds a
doctorate in biochemistry and molecular developmental biology and genetics, a
master's degree in biology and international patent law and a bachelor's
degree in biology and geography.
As MedImmune's new vice president, global strategic marketing and
portfolio management, Dr. Reginald Seeto is responsible for providing
strategic guidance on investment decisions and managing commercialization
efforts for new products in various stages of development. In his previous
position at Organon International, he was the vice president of global
marketing, fertility, immunology, oncology and vaccines. Previously, Dr. Seeto
was the executive director of marketing at Boehringer Ingelheim
Pharmaceuticals and had served as an engagement manager at McKinsey & Company.
He holds both a medical degree and a bachelor of science degree from the
University of Sydney, and practiced medicine in Australia early in his career.
MedImmune strives to provide better medicines to patients, new medical
options for physicians and rewarding careers to employees. Dedicated to
advancing science and medicine to help people live better lives, the company
is focused on infection, oncology, respiratory disease and inflammation,
cardiovascular/gastrointestinal disease and neuroscience. With approximately
3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly
owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit
MedImmune's website at http://www.medimmune.com.
/CONTACT: Media, Jamie Lacey, +1-301-398-4035, or Investors, Peter Vozzo,
+1-301-398-4358, both of MedImmune/
/Web site: http://www.medimmune.com /
CO: MedImmune; AstraZeneca plc
ST: Maryland, England, Netherlands
IN: BIO MTC HEA
-- NETU091 --
9726 05/06/2008 09:34 EDT http://www.prnewswire.com